CanSino Biologics (HKG:6185, SHA:688185) said its new drug application for tetanus vaccine was accepted by the National Medical Products Administration of China, a Thursday bourse filing said.

Tetanus, a severe infectious disease, is caused by Clostridium tetani with a mortality rate reaching 30%-50% with medical intervention while the rate stands at 100% without medical intervention.

The vaccine, developed by the company, is aimed at non-neonatal tetanus prevention. It is safer as it is fermented with an animal-free culture medium, the filing said.